Tilbake til søkeresultatene

FUGE-Funksjonell genomforskn.i Norg

Advanced MR imaging, MR metabolomics, proteomics and genetic mapping of breast cancer - Clinical tools for personalized patient treatment

Tildelt: kr 5,2 mill.

Breast cancer has the highest incidence and mortality of all malignant diseases among women globally. The heterogeneous nature of breast cancer results in different clinical presentations and outcomes, and patients show a diverse range of responses to a g iven treatment. Processes leading to more effective diagnosis and treatment will result in improved outcome. This project aims at developing an efficient and effective process to integrate molecular biomarkers and advanced imaging for rapid implementation in clinical practice. Genomics, proteomics, MR metabolomics ("omics" techniques) and advanced imaging will be combined to aid the clinical management of breast cancer patients. For the purpose of further development of the combined methodologies and the understanding of basic mechanisms, breast cancer model systems (xenograft models) will be studied in parallel to the clinical projects. The simple translation of methodology from basic research to clinical practise is one of the main advantages with MR im aging. We also aim to introduce and further develop a new technology; MR metabolomics. The introduction of MR metabolomics as a new technology within FUGE II will be an important contribution to complete the diversity of services for research within syste ms biology. Extensive collaboration with national as well as international highly ranked research groups are established in order to obtain these objectives, and a significant amount of technology transfer is anticipated from the extensive stays abroad, b oth in Europe and USA, which are scheduled for the PhD candidates.

Budsjettformål:

FUGE-Funksjonell genomforskn.i Norg